Tumorimmuntherapy associated neurological adverse events

Tumorimmuntherapy associated neurological adverse events - TITAN2

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012668

Enrollment

200

Registered

2017-07-10

Start date

2017-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Y57.9

Interventions

Group 1: Patients under immune checkpoint inhibitor therapy will be observed for 12 months after treatment initiation. Visits in regular time intervals include a neurological examinations, electrophys

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Treatment with immune checkpoint inhibitor

Exclusion criteria

Exclusion criteria: Not able to consent. Persons under official or judicial custody. Contraindications for blood draw.

Design outcomes

Primary

Measure	Time frame
First clinical presentation of a neurological irAE during the observation period of 12 months after treatment initiation.	—

Secondary

Measure	Time frame
Sub-clinical signs of a neurological irAE	—

Countries

Germany

Contacts

Public ContactSamuel Knauss

Charité Campus Charité Mitte

samuel.knauss@charite.de030450560137

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 10, 2026